All questionsPharmacology: Vabysmo (faricimab-svoa), all indications6 questions · 2 sourcesMechanismHow does Vabysmo work (mechanism of action)?“Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD, DME, and RVO. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD, DME, and RVO has yet to be established.” (opens the source at this quote in a new tab)CopyFlagHow long does Vabysmo suppress Ang-2 and VEGF-A after a dose?“VABYSMO suppressed Ang-2 and VEGF-A for up to 16 weeks after initial dosing1,9†” (opens the source at this quote in a new tab)CopyFlag“Pharmacodynamic analysis in aqueous humor of patients with nAMD or DME in Phase 2 and 3 trials: Ang-2 and VEGF-A levels did not return to baseline 16 weeks after a dose.9” (opens the source at this quote in a new tab)CopyFlag“The contribution of Ang-2 inhibition to the clinical response for nAMD, DME, and RVO has yet to be established.1” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsHow is Vabysmo metabolized?“Metabolism and elimination of faricimab has not been fully characterized. Faricimab is expected to be catabolized in lysosomes to small peptides and amino acids, which may be excreted renally, in a similar manner to the elimination of endogenous IgG.” (opens the source at this quote in a new tab)CopyFlagHow long does Vabysmo stay in your system (half-life)?“The estimated mean apparent systemic half-life of faricimab is approximately 7.5 days.” (opens the source at this quote in a new tab)CopyFlag“Maximum faricimab plasma concentrations (Cmax) are estimated to occur approximately 2 days post-dose.” (opens the source at this quote in a new tab)CopyFlagDoes Vabysmo build up in the body with repeated injections?“After repeated intravitreal administrations, mean plasma free faricimab trough concentrations are predicted to be 0.002-0.003 mcg/mL for every 8 weeks (Q8W) dosing and 0.021-0.029 mcg/mL for every 4 weeks (Q4W) dosing. Although not directly measured in the vitreous, no accumulation of faricimab is expected in the vitreous and no accumulation has been observed in plasma when faricimab has been administered as repeat doses in the vitreous.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the inactive ingredients in Vabysmo?“VABYSMO (faricimab-svoa) injection is a sterile, clear to opalescent, colorless to brownish-yellow solution in a single-dose prefilled glass syringe or glass vial for intravitreal administration. Each single-dose prefilled syringe or single-dose vial is designed to deliver 0.05 mL (50 microliters) of solution containing 6 mg faricimab-svoa, L-histidine (155 mcg), L- methionine (52.2 mcg), polysorbate 20 (20 mcg), sodium chloride (73.1 mcg), D-sucrose (2.74 mg) and Water for Injection, adjusted to pH 5.5 with acetic acid. The product does not contain an anti-microbial preservative.” (opens the source at this quote in a new tab)CopyFlag